Retigabine approved for epilepsy
Retigabine has been approved for controlling seizures in adults with epilepsy by the National Institute for Health and Clinical Excellence.
New guidance published this week (27 July 2011) recommends retigabine (Trobolt; GlaxoSmithKline) treatment for adults with partial onset seizures (with or without secondary generalisation) as an add-on treatment option.
Patients should only be treated with retigabine if the following drugs have been ineffective or caused unmanageable side effects: carbamazepine, clobazam, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate and topiramate.
Citation: The Pharmaceutical Journal URI: 11081422
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com